Your session is about to expire
← Back to Search
This trial is exploring whether a different cancer drug is safe for people with a specific type of blood cancer who are already taking a different drug.
- Waldenstrom Macroglobulinemia
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2022 Phase 2 trial • 54 Patients • NCT03023046
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You are currently receiving treatment for any other cancer, except for skin cancer that is being treated with creams or ointments.You have a history of not following your doctor's instructions for taking medication or following medical advice.You are currently taking strong medications that can affect the way other drugs work in your body.You are taking St. John's Wort. You need to stop taking it at least 5 days before starting dasatinib.Taking medication like Zantac or Prilosec for stomach issues.You have symptoms of a disease that need to be treated based on specific guidelines.You have a certain type of protein in your blood called immunoglobulin M (IgM) at a high level.You have a performance status of 2 or lower, based on how well you can carry out daily activities.Your organs and bone marrow need to be working normally.You have been diagnosed with Waldenstrom's Macroglobulinemia.Your tumor has a specific gene mutation called MYD88, as confirmed by a certified laboratory test.You need to have a specific BTKCys481 and/or PLCγ2 mutation confirmed by a certain laboratory test.You must have received at least one treatment before, with ibrutinib being the most recent one. If you are currently taking ibrutinib, you will need to stop for one day before starting dasatinib.Your disease got worse while you were taking ibrutinib as your last treatment, based on specific guidelines.You have previously been treated with BCR-ABL inhibitors.You have been diagnosed with central nervous system (CNS) lymphoma.You have a condition that requires immediate treatment for thickened blood.You have HIV, active Hepatitis B, or active Hepatitis C.You have a history of alcohol or drug abuse.Your heart's electrical activity takes too long to reset between beats, as shown on a test called an electrocardiogram.You have a history of serious heart rhythm problems.
- Group 1: Dasatinib
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the participant quota for this experiment?
"Affirmative. Clinicaltrials.gov provides information that this medical research project, which commenced on November 4th 2019, is presently looking for volunteers to participate in the study. 6 participants are sought at one site."
To what extent does Dasatinib pose a health risk to patients?
"Due to the limited efficacy and safety data associated with Dasatinib, our team has rated its safety a 1 on a scale of 1-3."
Are there any prior investigations into Dasatinib's efficacy?
"Currently, 64 Dasatinib-based trials are in progress with 9 studies at the Phase 3 stage. While New York City has a high concentration of these clinical tests, there are 4258 sites conducting research on this drug across the US."
Is recruitment still open for volunteers to participate in this experiment?
"Currently, this research project is open to recruitment. It was initially published on November 4th 2019 and had a recent update as of March 22nd 2022 according to clinicaltrials.gov."
Share this study with friends